Display options
Cite
Wester R, Zweegman S, van der Holt B, et al. Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. Hemasphere. 2020;4(4):e370doi: 10.1097/HS9.0000000000000370.
Wester, R., Zweegman, S., van der Holt, B., Kersten, M. J., Vellenga, E., van Marwijk-Kooy, M., Asselbergs, E., de Weerdt, O., Minnema, M. C., Lonergan, S., Palumbo, A., Broijl, A., & Sonneveld, P. (2020). Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. HemaSphere, 4(4), e370. https://doi.org/10.1097/HS9.0000000000000370
Wester, Ruth, et al. "Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial." HemaSphere vol. 4,4 (2020): e370. doi: https://doi.org/10.1097/HS9.0000000000000370
Wester R, Zweegman S, van der Holt B, Kersten MJ, Vellenga E, van Marwijk-Kooy M, Asselbergs E, de Weerdt O, Minnema MC, Lonergan S, Palumbo A, Broijl A, Sonneveld P. Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. Hemasphere. 2020 Aug 12;4(4):e370. doi: 10.1097/HS9.0000000000000370. eCollection 2020 Aug. PMID: 32885140; PMCID: PMC7437562.
Copy Download .nbib Format: NLM
Share it on

Hemasphere. 2020 Aug 12;4(4):e370. doi: 10.1097/HS9.0000000000000370. eCollection 2020 Aug.

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial.

HemaSphere

Ruth Wester, Sonja Zweegman, Bronno van der Holt, Marie José Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, Emelie Asselbergs, Okke de Weerdt, Monique C Minnema, Sarah Lonergan, Antonio Palumbo, Annemiek Broijl, Pieter Sonneveld

Affiliations

  1. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  2. Department of Hematology, Amsterdam UMC, The Netherlands.
  3. HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  4. Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  5. Department of Hematology, Isala Clinics, Zwolle, The Netherlands.
  6. Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands.
  7. Department of Hematology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.
  8. Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, University of Turin, Turin, Italy.

PMID: 32885140 PMCID: PMC7437562 DOI: 10.1097/HS9.0000000000000370

[No abstract available.]

Conflict of interest statement

The authors have indicated that they have no potential conflicts of interest to disclose.

References

  1. Haematologica. 2019 Nov;104(11):2265-2273 - PubMed
  2. Haematologica. 2010 Oct;95(10):1738-44 - PubMed
  3. Lancet Oncol. 2016 Jan;17(1):27-38 - PubMed
  4. Lancet. 2019 Jul 6;394(10192):29-38 - PubMed
  5. J Clin Oncol. 2008 Dec 10;26(35):5775-82 - PubMed
  6. Blood. 2012 Sep 27;120(13):2581-8 - PubMed

Publication Types